C4 Therapeutics, Inc. reported a net loss of $26.322 million for the three months ended March 31, 2025, an improvement from the $28.361 million net loss in the same period last year. Revenue from collaboration agreements significantly increased to $7.238 million from $3.039 million year-over-year. Total assets decreased to $319.524 million from $349.602 million at the end of 2024.

C4 Therapeutics reported increased revenue for Q4 2024, primarily driven by new collaborations. The company's net loss remained relatively flat compared to the prior year, and its cash position is expected to provide a runway into 2027.

C4 Therapeutics reported Q3 2024 revenue of $15.4 million compared to $11.1 million for Q3 2023. Net loss for the quarter was $24.7 million, or $0.35 per share, compared to a net loss of $27.0 million, or $0.55 per share, for the third quarter of 2023. Cash, cash equivalents and marketable securities totaled $284.4 million as of September 30, 2024, expected to provide runway into 2027.

C4 Therapeutics reported a net loss of $17.7 million for Q2 2024, with total revenue of $12.0 million. The company's cash, cash equivalents, and marketable securities totaled $295.7 million as of June 30, 2024, expected to fund operations into 2027.

C4 Therapeutics reported a net loss of $28.4 million for the first quarter of 2024, with total revenue of $3.0 million. The company's cash, cash equivalents, and marketable securities totaled $299.2 million as of March 31, 2024, expected to provide runway into 2027. They delivered a development candidate to Biogen, earning an $8 million payment, and established a strategic discovery research collaboration with Merck KGaA, Darmstadt, Germany.

C4 Therapeutics reported its full year 2023 financial results, highlighting progress in clinical trials for CFT7455 and CFT1946, new collaborations with Merck and Betta Pharmaceuticals, and a workforce reduction to streamline research efforts. The company's cash runway is expected to extend into 2027.

C4 Therapeutics reported a net loss of $27.0 million for Q3 2023, with revenue of $11.1 million. The company's cash, cash equivalents, and marketable securities totaled $246.4 million as of September 30, 2023, expected to provide runway into 2H 2025. A portfolio decision was made to not advance CFT8634 in Synovial Sarcoma and SMARCB-1 Null Tumors.

C4 Therapeutics reported a revenue of $2.7 million and a net loss of $35.9 million for the second quarter of 2023. The company's cash, cash equivalents, and marketable securities totaled $286.7 million as of June 30, 2023, expected to provide runway into the second half of 2025.

C4 Therapeutics reported a net loss of $34.8 million for the first quarter of 2023, with revenue of $3.8 million. The company's cash, cash equivalents, and marketable securities totaled $305.0 million as of March 31, 2023, expected to provide runway into 2025.

C4 Therapeutics reported its financial results for the year ended December 31, 2022. The company's year-end cash, cash equivalents, and marketable securities are expected to provide runway to the end of 2024.

C4 Therapeutics reported a net loss of $32.0 million for the third quarter of 2022, with revenue of $6.8 million. The company's cash, cash equivalents, and marketable securities totaled $366.0 million as of September 30, 2022, expected to provide runway to the end of 2024.

C4 Therapeutics reported a revenue of $13.8 million for the second quarter of 2022, compared to $9.8 million for the second quarter of 2021. Net loss for the quarter was $27.4 million, or $0.56 per share, compared to a net loss of $22.6 million, or $0.51 per share, for the second quarter of 2021. Cash, cash equivalents and marketable securities totaled $397.8 million as of June 30, 2022.

C4 Therapeutics reported first quarter 2022 financial results, highlighting clinical data from the CFT7455 Phase 1/2 trial presented at AACR and the initiation of a Phase 1/2 clinical trial for CFT8634. The company's cash, cash equivalents, and marketable securities totaled $421.7 million as of March 31, 2022, expected to provide runway to the end of 2024.

C4 Therapeutics reported its full year 2021 financial results, highlighting progress across its organization, including dosing the first patient with its lead program and advancing additional candidates towards the clinic. The company's cash, cash equivalents, and marketable securities are expected to provide runway to the end of 2024.

C4 Therapeutics reported third quarter 2021 revenue of $8.5 million, a net loss of $24.7 million, and a net loss per share of $0.51. The company's cash, cash equivalents, and marketable securities totaled $480.3 million as of September 30, 2021. C4T is on track to achieve four clinical programs by year-end 2022.

C4 Therapeutics reported a revenue of $9.8 million for the second quarter of 2021, slightly up from $9.7 million in the same period last year. The company's net loss was $22.6 million, or $0.51 per share. As of June 30, 2021, C4 Therapeutics had cash, cash equivalents, and marketable securities totaling $498.7 million.